Accendra Health CFO granted 85,067 restricted shares

Leon Jonathan A reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Leon Jonathan A reported acquisition or exercise transactions in this Form 4 filing.

ACCENDRA HEALTH INC/VA/ EVP & CFO Jonathan A. Leon received a grant of 85,067 shares of common stock. The shares are restricted stock that vest one-third per year over three years, meaning they become fully owned gradually over time. After this award, he directly holds 303,589 common shares. This is a compensation-related equity grant at no cash cost and does not involve any open-market buying or selling.

Insights

Equity compensation analyst

CFO received a time-vested stock grant, a routine non-cash compensation event.

The EVP & CFO of ACCENDRA HEALTH INC/VA/, Jonathan A. Leon, was granted 85,067 shares of common stock as restricted stock, vesting in equal installments over three years. The award price is reported as $0.0000 per share, consistent with a compensation grant rather than a market purchase.

Following this grant, Leon directly holds 303,589 shares of common stock. Because this is a standard equity award with no open-market transactions, it mainly aligns the executive’s interests with shareholders instead of signaling a view on the current share price.

Insider Trade Summary

Grant/Award: 85,067 shares

Grant/Award 1 txn

Insider Leon Jonathan A

Role EVP & CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	85,067	$0.00	$0.00

Holdings After Transaction: Common Stock — 303,589 shares (Direct)

Footnotes (1)

1. F1. Restricted stock grant which vests one-third per year over three years.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ACCENDRA HEALTH (ACH) disclose about its CFO in this Form 4?

ACCENDRA HEALTH reported that EVP & CFO Jonathan A. Leon received a grant of 85,067 restricted common shares. These shares vest over three years and are part of his equity compensation, rather than an open-market purchase or sale of stock.

How many ACCENDRA HEALTH (ACH) shares did the CFO acquire in this transaction?

The EVP & CFO acquired 85,067 shares of ACCENDRA HEALTH common stock through a restricted stock grant. This award increased his direct holdings to 303,589 shares, reflecting compensation rather than an investment trade on the open market.

How does the restricted stock grant for ACCENDRA HEALTH (ACH) CFO vest?

The 85,067-share restricted stock grant vests one-third per year over three years. This means the CFO gains full ownership gradually, encouraging longer-term alignment with company performance instead of an immediate, fully transferable stock award.

Did the ACCENDRA HEALTH (ACH) CFO buy or sell shares on the open market?

No open-market buy or sell occurred. The CFO received 85,067 shares as a restricted stock grant at a reported price of $0.0000 per share, indicating a compensation award rather than a discretionary market trade in ACCENDRA HEALTH stock.

What are the CFO’s total ACCENDRA HEALTH (ACH) holdings after this Form 4 transaction?

After the restricted stock grant, EVP & CFO Jonathan A. Leon directly holds 303,589 shares of ACCENDRA HEALTH common stock. This figure reflects his position following the equity award disclosed in the Form 4 filing with the SEC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 09:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leon Jonathan A

(Last) (First) (Middle)

ACCENDRA HEALTH, INC.

4435 WATERFRONT DRIVE

(Street)

GLEN ALLEN VA 23060

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACCENDRA HEALTH INC/VA/ [ ACH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/09/2026		A		85,067	A	$0	303,589	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock grant which vests one-third per year over three years.

	Jonathan A. Leon, by Rosemarie W. France POA	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.